fenofibrate has been researched along with 8-epi-prostaglandin f2alpha in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnett, D; Cao, J; Dong, Y; Hanson, NQ; Kabagambe, E; Ordovas, J; Steffen, BT; Straka, R; Tsai, AK; Tsai, MY; Zhou, X | 1 |
| Agouridis, AP; Dimitriou, AA; Elisaf, MS; Filippatos, TD; Mikhailidis, DP; Tellis, CC; Tselepis, AD; Tsimihodimos, V | 1 |
| Averna, M; Cefalù, AB; Davì, G; Ganci, A; Lattanzio, S; Noto, D; Puccetti, L; Saggini, R; Santoro, N; Vazzana, N | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 1 |
2 trial(s) available for fenofibrate and 8-epi-prostaglandin f2alpha
| Article | Year |
|---|---|
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Aryldialkylphosphatase; C-Reactive Protein; Dinoprost; Drug Combinations; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Inflammation; Lipids; Male; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
2 other study(ies) available for fenofibrate and 8-epi-prostaglandin f2alpha
| Article | Year |
|---|---|
Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants.
Topics: Atherosclerosis; Biomarkers; Cohort Studies; Dinoprost; Fenofibrate; Genetic Predisposition to Disease; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Oxidative Stress; Time Factors; Treatment Outcome; Triglycerides; United States | 2011 |
Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype.
Topics: Aged; Arachidonic Acids; Case-Control Studies; Cholesterol, HDL; Coronary Disease; Cross-Sectional Studies; Dinoprost; Exercise; Exercise Therapy; Female; Fenofibrate; Humans; Hypoalphalipoproteinemias; Hypolipidemic Agents; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Phenotype; Platelet Activation; Risk Factors; Sedentary Behavior; Thromboxane B2 | 2013 |